Home Newsfeeds William Blair Initiates Coverage On ON Semiconductor with Outperform Rating

William Blair Initiates Coverage On ON Semiconductor with Outperform Rating

William Blair analyst Jed Dorsheimer initiates coverage on ON Semiconductor (NASDAQ:ON) with a Outperform rating.

byBenzinga Newsdesk

October 17, 2022

1 minute read

William Blair analyst Jed Dorsheimer initiates coverage on ON Semiconductor (NASDAQ:ON) with a Outperform rating.

Apple’s High-Yield Savings Account Will Take A Leaf Out Of ‘iPhone Playbook,’ Says Analyst: ‘Gonna Be Another Huge Profit Center’

By Shanthi Rexaline

April 29, 2:21 PM

Apple, Inc. (NASDAQ:AAPL) stirred up excitement by announcing earlier this month a high-yielding savings account that promises an…

AAPL

News

Cineverse Enlists Top AI Companies Vionlabs And Datatonic To Further Enhance Content Discovery Tool cineSearch

By Benzinga Newsdesk

April 10, 1:39 PM

Built in Collaboration With Google Cloud's Gen AI Technology, cineSearch Will Be the Most Advanced Search and Discovery Tool for Film and Television ContentLOS ANGELES, April 10, 2024 /PRNewswire/ -- Cineverse

CNVS

Adobe Well-Positioned To Gain From Digital Transformation, Analysts Say

By Anusuya Lahiri

December 12, 3:28 PM

Mizuho analyst Gregg Moskowitz reiterated a Neutral on Adobe Inc (NASDAQ: ADBE) with a $3

ADBE

Adaptimmune Reported 44% Objective Response Rate With a Single Dose of ADP-A2M4CD8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers

By Charles Gross

September 9, 7:03 AM

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial.

ADAP

William Blair Initiates Coverage On ON Semiconductor with Outperform Rating

Related Posts

Apple’s High-Yield Savings Account Will Take A Leaf Out Of ‘iPhone Playbook,’ Says Analyst: ‘Gonna Be Another Huge Profit Center’

Cineverse Enlists Top AI Companies Vionlabs And Datatonic To Further Enhance Content Discovery Tool cineSearch

Adobe Well-Positioned To Gain From Digital Transformation, Analysts Say

Adaptimmune Reported 44% Objective Response Rate With a Single Dose of ADP-A2M4CD8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers